RBC sees nearly 30% upside for this medical tech stock as headwinds abate
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
a day ago
- CNBC
RBC's Croft on Trump-Putin talks: Russian gas flowing into Europe is 'getting way too ahead'
Helima Croft, RBC Capital Markets managing director, joins 'Power Lunch' to discuss what to expect from the meeting between Trump and Putin, Russia's financials and much more.
Yahoo
2 days ago
- Yahoo
Abbott, Siemens Healthineers, and Thermo Fisher Scientific Lead the Market with Innovative Portfolios and Strategic Expansion
The HIV Diagnostics Companies Quadrant report offers an in-depth analysis of the global HIV diagnostics market, assessing over 100 companies and highlighting the Top 14 leaders. Market expansion is driven by rising HIV/AIDS prevalence, point-of-care technological advancements, and awareness campaigns. However, high costs and skilled technician shortages hinder growth. North America leads in market dominance due to its HIV/AIDS prevalence and advanced technologies, while Asia Pacific is projected to grow fastest. Key players like Abbott, Siemens Healthineers, and Thermo Fisher Scientific employ strategies like acquisitions and innovations to maintain strong market positions amid evolving trends. Dublin, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The "HIV Diagnostics - Company Evaluation Report, 2025" report has been added to HIV Diagnostics Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for HIV Diagnostics. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and emerging trends shaping the industry. 360 Quadrants evaluated over 100 companies, of which the Top 14 HIV Diagnostics Companies were categorized and recognized as the quadrant growth can be attributed to the rising prevalence of HIV/AIDS, the advantages offered by point-of-care instruments & kits, and increasing initiatives for HIV awareness campaigns. However, the high cost of NATs, operational barriers, and the shortage of skilled laboratory technicians are key factors restraining the market growth. The high growth potential of emerging economies and the trend of self-testing are expected to provide lucrative opportunities for market players during the forecast HIV diagnostics market is segmented into six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries. North America dominated the global market in 2023. Factors such as the rising prevalence of HIV/AIDS, advancements in PoC instruments and kits, increasing awareness about HIV/AIDS, and increasing blood transfusion and blood donations are driving the growth of the HIV diagnostics market in North the Asia Pacific market is expected to grow at the highest CAGR during the forecast period. The high growth rate of the Asia Pacific market can be attributed to the rising target patient population; the expansion of emerging economies; the increasing availability of technologically advanced POC products; favorable government initiatives for HIV awareness; and the growing expansion of global players in this Players:Key players in this market include Abbott (US), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland). These players adopt various strategies, such as product launches, expansions, acquisitions, and collaborations, to excel in this (US)Abbott is a leading player in the HIV diagnostics market, known for its impactful Company Product Portfolio that includes FDA- and CE-approved products. The company's strong Company Market Share in the U.S. is complemented by its strategic focus on expanding its presence in emerging markets through varied Company Positioning strategies. By leveraging inorganic growth strategies, such as collaborations and acquisitions, Abbott aims to bolster its Company Healthineers AG (Germany)Siemens Healthineers is a cornerstone in the HIV diagnostics sphere, providing a broad array of medical solutions. Their focus on organic strategies and innovation has allowed them to maintain a competitive Company Positioning. With a significant presence in Europe, America, and emerging markets, they continue to excel in Company Market Share by offering innovative products that meet health sector Fisher Scientific (US)With a comprehensive Company Product Portfolio that spans PCR-based assays and immunoassays, Thermo Fisher Scientific remains a leader. Their strategies focus on regulatory approvals and strategic acquisitions to enhance their Company Market Share. Through collaboration with healthcare organizations, they aim to boost early HIV detection and improve global health access, effectively securing their Company Positioning and Company Ranking in the Topics Covered: 1 Introduction1.1 Market Definition1.2 Inclusions & Exclusions1.3 Stakeholders2 Executive Summary3 Market Overview3.1 Introduction3.2 Market Dynamics3.2.1 Drivers3.2.1.1 Rising Prevalence of Hiv/Aids3.2.1.2 Increasing Number of Blood Transfusions & Blood Donations3.2.1.3 Advantages Offered by Poc Diagnostic Kits & Instruments3.2.1.4 Increasing Initiatives for Hiv Awareness Campaigns3.2.2 Restraints3.2.2.1 High Cost of Nats3.2.3 Opportunities3.2.3.1 High Growth Potential of Emerging Economies3.2.3.2 Trend of Self-Testing and Growing Preference for At-Home Diagnostic Kits3.2.4 Challenges3.2.4.1 Operational Barriers and Shortage of Skilled Laboratory Technicians3.3 Trends/Disruptions Impacting Customers' Businesses3.4 Value Chain Analysis3.5 Supply Chain Analysis3.6 Ecosystem Analysis3.7 Technology Analysis3.7.1 Key Technologies3.7.1.1 Elisa3.7.2 Complementary Technologies3.7.2.1 Western Blot Tests3.7.3 Adjacent Technologies3.7.3.1 Pcr3.8 Patent Analysis3.9 Key Conferences & Events, 2025-20263.10 Porter's Five Forces Analysis3.10.1 Threat of New Entrants3.10.2 Threat of Substitutes3.10.3 Bargaining Power of Buyers3.10.4 Bargaining Power of Suppliers3.10.5 Intensity of Competitive Rivalry3.11 Impact of Ai/Generative Ai on Hiv Diagnostics Market3.11.1 Market Potential of Ai in Hiv Diagnostics3.11.2 Ai Use Cases3.11.3 Company Implementation of Ai3.11.4 Future of Ai/Generative Ai4 Competitive Landscape4.1 Overview4.2 Key Player Strategies/Right to Win4.2.1 Overview of Strategies Adopted by Key Players in Hiv Diagnostics Market4.3 Revenue Analysis, 2021-20234.4 Market Share Analysis, 20234.4.1 Ranking of Key Market Players4.5 Company Evaluation Matrix: Key Players, 20234.5.1 Stars4.5.2 Emerging Leaders4.5.3 Pervasive Players4.5.4 Participants4.5.5 Company Footprint: Key Players, 20234.5.5.1 Company Footprint4.5.5.2 Region Footprint4.5.5.3 Product Footprint4.5.5.4 End-User Footprint4.6 Company Evaluation Matrix: Startups/Smes, 20234.6.1 Progressive Companies4.6.2 Responsive Companies4.6.3 Dynamic Companies4.6.4 Starting Blocks4.6.5 Competitive Benchmarking: Startups/Smes, 20234.6.5.1 Detailed List of Key Startups/Sme Players4.6.5.2 Competitive Benchmarking of Key Startups/Smes4.7 Company Valuation & Financial Metrics4.8 Brand/Product Comparison4.9 Competitive Scenario4.9.1 Product/Service Launches & Approvals4.9.2 Product Launches & Approvals4.9.3 Deals4.9.4 Expansions4.9.5 Other Developments5 Company Profiles Abbott Siemens Healthineers Grifols, S.A. Danaher Corporation Thermo Fisher Scientific Inc. Bio-Rad Laboratories, Inc. F. Hoffmann-La Roche Ltd. Biomerieux Hologic, Inc. Qiagen Bd Trinity Biotech Orasure Technologies, Inc. Biosynex Sa Wondfo Getein Biotech, Inc. Meril Life Sciences Pvt. Ltd. Accubiotech Co., Ltd. Biolytical Laboratories Inc. Bio Lab Diagnostics (I) Private Limited Alpine Biomedicals Pvt Ltd. Molbio Diagnostics Pvt. Ltd. Fortress Diagnostics Advacare Pharma (Accuquik) Adaltis S.R.L. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
What Are Wall Street Analysts' Target Price for Hologic Stock?
Marlborough, Massachusetts-based Hologic, Inc. (HOLX) develops, manufactures, and supplies diagnostic products, imaging systems, and surgical products for women's health, helping in the early detection and treatment of diseases worldwide. With a market cap of $15.1 billion, Hologic operates through Diagnostics, Breast Health, GYN Surgical, and Skeletal Health segments. The company has significantly underperformed the broader market over the past year. HOLX stock has declined 15.4% over the past 52 weeks and 4.3% on a YTD basis, lagging behind the S&P 500 Index's ($SPX) 19% surge over the past year and 10% returns in 2025. More News from Barchart Why This Cannabis Penny Stock Could Be Wall Street's Next Meme Trade Breakout Peter Thiel-Backed Bullish Is About to IPO. Should You Buy BLSH Stock? Apple Stock Is Gaining Momentum, Is AAPL Stock a Buy? Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! Narrowing the focus, Hologic has also underperformed the industry-focused iShares U.S. Medical Devices ETF's (IHI) 10.3% gains over the past 52 weeks and 5.9% returns in 2025. While Hologic has underperformed the broader market over the past year, it has observed significant gains in recent months. Its stock prices have shot up more than 20% in the past three months alone. Further, HOLX stock gained 2.8% in the trading session following the release of its better-than-expected Q3 results on Jul. 30. The company's topline for the quarter inch up 1.2% year-over-year to $1.02 billion, surpassing the consensus estimates by 1.7%. Moreover, its adjusted EPS grew by 1.9% to $1.08, coming ahead of the management's guidance range and beating the Street's expectations by 2.9%. For the full fiscal 2025, ending in September, analysts expect Hologic to deliver an adjusted EPS of $4.24, up 3.9% year-over-year. The company has a mixed earnings surprise history. While it missed the Street's bottom-line estimates once over the past four quarters, it surpassed the projections on three other occasions. The stock has a consensus 'Moderate Buy' rating overall. Of the 19 analysts covering the stock, opinions include six 'Strong Buys,' two 'Moderate Buys,' and 11 'Holds.' This configuration is slightly more optimistic than two months ago, when five analysts gave 'Strong Buy' recommendations and only one analyst suggested a 'Moderate Buy' rating. On Aug. 6, RBC Capital analyst Conor McNamara upgraded HOLX from 'Sector Perform' to 'Outperform' and raised the price target from $72 to $87. As of writing, Hologic's mean price target of $73 suggests a modest 5.8% upside potential from current price levels. On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
